Followers | 9842 |
Posts | 260003 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
![](https://investorshub.advfn.com/uicon/89929.png?cb=1464345786)
Tuesday, May 18, 2021 5:47:10 PM
Link to Video - click here to watch the technical chart video
Recent AGEN News
- Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer • Business Wire • 07/18/2024 11:00:00 AM
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
- Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors • Business Wire • 06/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:02:11 PM
- Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50 • Business Wire • 06/13/2024 09:15:00 AM
- Agenus Announces Virtual Annual Shareholders Meeting • Business Wire • 06/04/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:01:10 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/24/2024 09:00:00 PM
- Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting • Business Wire • 05/23/2024 09:10:00 PM
- Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 05/23/2024 11:30:00 AM
- FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer • Business Wire • 05/16/2024 11:30:00 AM
- Agenus Reports First Quarter 2024 Results • Business Wire • 05/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:39:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:38:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:31:13 AM
- Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 05/01/2024 11:30:00 AM
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting • Business Wire • 04/24/2024 02:00:00 PM
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update • Business Wire • 04/23/2024 11:30:00 AM
- Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer • Business Wire • 04/12/2024 11:30:00 AM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM